Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Abbott Laboratories
  6. News
  7. Summary
    ABT   US0028241000

ABBOTT LABORATORIES

(ABT)
  Report
Delayed Nyse  -  05/26 04:03:39 pm EDT
114.87 USD   +1.48%
12:47pAbbott Laboratories Recalls Dragonfly OpStar Imaging Catheter on Concerns Loose Marker Band Could Cause Harm
MT
11:35aAbbott Laboratories Recalls Dragonfly Opstar Imaging Catheter As Potential Loose Market Band Could Cause Patient Harm
MT
05/25TIMELINE : Baby formula crunch in U.S. forces scramble to boost supplies
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Abbott Laboratories Secures FDA Clearance for Ensite Cardiac Mapping Platform

01/12/2022 | 09:43am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ABBOTT LABORATORIES 1.48% 114.87 Delayed Quote.-18.38%
ON SEMICONDUCTOR CORPORATION 5.49% 59.33 Delayed Quote.-12.65%
All news about ABBOTT LABORATORIES
12:47pAbbott Laboratories Recalls Dragonfly OpStar Imaging Catheter on Concerns Loose Marker ..
MT
11:35aAbbott Laboratories Recalls Dragonfly Opstar Imaging Catheter As Potential Loose Market..
MT
05/25TIMELINE : Baby formula crunch in U.S. forces scramble to boost supplies
RE
05/25Abbott to release elecare amino acid-based formulas to help meet critical patient need
AQ
05/25MARKETSCREENER'S WORLD PRESS REVIEW : May 25, 2022
05/25Abbott to Release Limited Quantities of EleCare Formula Milk
MT
05/25Danone, Reckitt race to ramp up US baby formula supply amid shortage
RE
05/24Abbott to Release EleCare® Amino Acid-based Formulas to Help Meet Critical Patient Need
PR
05/24Abbott to Release EleCare® Amino Acid-Based Formulas to Help Meet Critical Patient Need
CI
05/24U.S. FTC launches inquiry into infant formula shortage
RE
More news
Analyst Recommendations on ABBOTT LABORATORIES
More recommendations
Financials (USD)
Sales 2022 41 813 M - -
Net income 2022 6 805 M - -
Net Debt 2022 4 167 M - -
P/E ratio 2022 30,7x
Yield 2022 1,67%
Capitalization 201 B 201 B -
EV / Sales 2022 4,91x
EV / Sales 2023 4,88x
Nbr of Employees 113 000
Free-Float 87,5%
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Last Close Price 114,87 $
Average target price 137,43 $
Spread / Average Target 19,6%
EPS Revisions
Managers and Directors
Robert B. Ford Chairman, President, Chief Executive Officer & COO
Robert Emmett Funck Chief Financial Officer & Executive VP-Finance
Sabina Ewing Chief Investment Officer, VP-Business & Technology
Glenn Fletcher Tilton Independent Director
William A. Osborn Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ABBOTT LABORATORIES-18.38%198 189
MEDTRONIC PLC2.02%141 586
BECTON, DICKINSON AND COMPANY2.60%71 882
HOYA CORPORATION-19.84%39 348
BAXTER INTERNATIONAL INC.-12.41%37 860
AMERISOURCEBERGEN CORPORATION15.19%32 314